Literature DB >> 15709015

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.

Michael S Seaman1, Ling Xu, Kristin Beaudry, Kristi L Martin, Margaret H Beddall, Ayako Miura, Anna Sambor, Bimal K Chakrabarti, Yue Huang, Robert Bailer, Richard A Koup, John R Mascola, Gary J Nabel, Norman L Letvin.   

Abstract

The development of a human immunodeficiency virus type 1 (HIV-1) vaccine that elicits potent cellular and humoral immune responses recognizing divergent strains of HIV-1 will be critical for combating the global AIDS epidemic. The present studies were initiated to examine the magnitude and breadth of envelope (Env)-specific T-lymphocyte and antibody responses generated by vaccines containing either a single or multiple genetically distant HIV-1 Env immunogens. Rhesus monkeys were immunized with DNA prime-recombinant adenovirus boost vaccines encoding a Gag-Pol-Nef polyprotein in combination with either a single Env or a mixture of clade-A, clade-B, and clade-C Envs. Monkeys receiving the multiclade Env immunization developed robust immune responses to all vaccine antigens and, importantly, a greater breadth of Env recognition than monkeys immunized with vaccines including a single Env immunogen. All groups of vaccinated monkeys demonstrated equivalent immune protection following challenge with the pathogenic simian-human immunodeficiency virus 89.6P. These data suggest that a multicomponent vaccine encoding Env proteins from multiple clades of HIV-1 can generate broad Env-specific T-lymphocyte and antibody responses without antigenic interference. This study demonstrates that it is possible to generate protective immune responses by vaccination with genetically diverse isolates of HIV-1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15709015      PMCID: PMC548456          DOI: 10.1128/JVI.79.5.2956-2963.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

Review 1.  Challenges and opportunities for development of an AIDS vaccine.

Authors:  G J Nabel
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

2.  Clonally diverse CTL response to a dominant viral epitope recognizes potential epitope variants.

Authors:  W A Charini; M J Kuroda; J E Schmitz; K R Beaudry; W Lin; M A Lifton; G R Krivulka; A Necker; N L Letvin
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

Review 3.  Vaccines for the prevention of HIV-1 disease.

Authors:  J R Mascola; G J Nabel
Journal:  Curr Opin Immunol       Date:  2001-08       Impact factor: 7.486

Review 4.  Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines.

Authors:  G Ferrari; D D Kostyu; J Cox; D V Dawson; J Flores; K J Weinhold; S Osmanov
Journal:  AIDS Res Hum Retroviruses       Date:  2000-09-20       Impact factor: 2.205

5.  Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines.

Authors:  A Kjerrström; J Hinkula; G Engström; V Ovod; K Krohn; R Benthin; B Wahren
Journal:  Virology       Date:  2001-05-25       Impact factor: 3.616

6.  Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.

Authors:  Bimal K Chakrabarti; Xu Ling; Zhi-Yong Yang; David C Montefiori; Amos Panet; Wing-Pui Kong; Brent Welcher; Mark K Louder; John R Mascola; Gary J Nabel
Journal:  Vaccine       Date:  2005-05-16       Impact factor: 3.641

7.  Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

Authors:  R Bures; A Gaitan; T Zhu; C Graziosi; K M McGrath; J Tartaglia; P Caudrelier; R El Habib; M Klein; A Lazzarin; D M Stablein; M Deers; L Corey; M L Greenberg; D H Schwartz; D C Montefiori
Journal:  AIDS Res Hum Retroviruses       Date:  2000-12-10       Impact factor: 2.205

8.  Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.

Authors:  D C Montefiori; K A Reimann; M S Wyand; K Manson; M G Lewis; R G Collman; J G Sodroski; D P Bolognesi; N L Letvin
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

9.  Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.

Authors:  N L Letvin; S Robinson; D Rohne; M K Axthelm; J W Fanton; M Bilska; T J Palker; H X Liao; B F Haynes; D C Montefiori
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

10.  Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines.

Authors:  A Fattom; Y H Cho; C Chu; S Fuller; L Fries; R Naso
Journal:  Vaccine       Date:  1999-01       Impact factor: 3.641

View more
  60 in total

1.  Stabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchange.

Authors:  Nichole Cerutti; Barry V Mendelow; Grant B Napier; Maria A Papathanasopoulos; Mark Killick; Makobetsa Khati; Wendy Stevens; Alexio Capovilla
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

2.  Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Authors:  Jeffrey D Lifson; Nancy L Haigwood
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

3.  Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine.

Authors:  Xueqing Lu; Shuzhen Wu; Catherine E Blackwell; Robert E Humphreys; Eric von Hofe; Minzhen Xu
Journal:  Immunology       Date:  2006-11-20       Impact factor: 7.397

4.  Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge.

Authors:  Yue Sun; Jörn E Schmitz; Adam P Buzby; Brianne R Barker; Srinivas S Rao; Ling Xu; Zhi-Yong Yang; John R Mascola; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

5.  A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

Authors:  Hua-Xin Liao; Laura L Sutherland; Shi-Mao Xia; Mary E Brock; Richard M Scearce; Stacie Vanleeuwen; S Munir Alam; Mildred McAdams; Eric A Weaver; Zenaido Camacho; Ben-Jiang Ma; Yingying Li; Julie M Decker; Gary J Nabel; David C Montefiori; Beatrice H Hahn; Bette T Korber; Feng Gao; Barton F Haynes
Journal:  Virology       Date:  2006-09-30       Impact factor: 3.616

6.  Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs.

Authors:  Yuuei Shu; Sarah Winfrey; Zhi-Yong Yang; Ling Xu; Srinivas S Rao; Indresh Srivastava; Susan W Barnett; Gary J Nabel; John R Mascola
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

7.  An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques.

Authors:  Zhanna Shubin; Weizhong Li; Bhawna Poonia; Guido Ferrari; Celia LaBranche; David Montefiori; Xiaoping Zhu; C David Pauza
Journal:  Clin Vaccine Immunol       Date:  2017-06-05

8.  Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.

Authors:  Mattias N E Forsell; Yuxing Li; Maria Sundbäck; Krisha Svehla; Peter Liljeström; John R Mascola; Richard Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs.

Authors:  Joseph P Nkolola; Hanqin Peng; Ethan C Settembre; Michael Freeman; Lauren E Grandpre; Colleen Devoy; Diana M Lynch; Annalena La Porte; Nathaniel L Simmons; Ritu Bradley; David C Montefiori; Michael S Seaman; Bing Chen; Dan H Barouch
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

Review 10.  HIV-1 vaccine development after STEP.

Authors:  Dan H Barouch; Bette Korber
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.